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Hereditary sensory and autonomic neuropathy type I (HSAN-I) is an axonal peripheral neuropathy associated with progressive distal
sensory loss and severe ulcerations. Mutations in the first subunit of the enzyme serine palmitoyltransferase (SPT) have been associated
with HSAN-I. The SPT enzyme catalyzes the first and rate-limiting step in the de novo sphingolipid synthesis pathway. However,
different studies suggest the implication of other genes in the pathology of HSAN-I. Therefore, we screened the two other known
subunits of SPT, SPTLC2 and SPTLC3, in a cohort of 78 HSAN patients. No mutations were found in SPTLC3, but we identified three
heterozygousmissensemutations in the SPTLC2 subunit of SPT in four families presentingwith a typical HSAN-I phenotype.We demon-
strate that these mutations result in a partial to complete loss of SPTactivity in vitro and in vivo. Moreover, they cause the accumulation
of the atypical and neurotoxic sphingoidmetabolite 1-deoxy-sphinganine. Our findings extend the genetic heterogeneity in HSAN-I and
enlarge the group of HSAN neuropathies associated with SPT defects. We further show that HSAN-I is consistently associated with an
increased formation of the neurotoxic 1-deoxysphinganine, suggesting a common pathomechanism for HSAN-I.Introduction
Hereditary sensory and autonomic neuropathy type I
(HSAN-I [MIM 162400]) is an autosomal-dominant periph-
eral neuropathy presenting from the second decade of life
onwards, with prominent sensory involvement and a vari-
able degree of motor and autonomic dysfunction. The
neurological phenotype is often complicated by severe
infections, osteomyelitis, and amputations. On nerve
conduction testing, sensory nerve action potentials are
typically severely reduced to absent with relative preserva-
tion of nerve conduction velocities, classifying HSAN-I as
an axonal neuropathy.1–3
HSAN-I has been reported to be associated with muta-
tions in the first subunit (SPTLC1 [MIM 605712]) of the
enzyme serine palmitoyltransferase (SPT).4–6 The SPT
enzyme is a multisubunit structure, consisting of dimeric
subunits of SPTLC1 with either SPTLC2 (MIM 605713) or
SPTLC3 (MIM 611120).7 It is associated with the endo-
plasmic reticulum (ER), where it catalyzes the pyridoxal-
50-phosphate (PLP)-dependent condensation of L-serine
with palmitoyl-CoA. This is the first and rate-limiting
step in the de novo biosynthesis of sphingolipids1Peripheral Neuropathy Group, VIB Department of Molecular Genetics, Univ
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components of all eukaryotic cells, with both structural
and signaling functions. Mutations in a high number of
enzymes involved in sphingolipid metabolism are associ-
ated with neurodegenerative diseases,9 highlighting the
importance of sphingolipids in neuronal functioning.
The HSAN-I-causing mutations in SPTLC1 result in
a significant reduction of SPT enzymatic activity, but the
effects on total sphingolipid levels remain controver-
sial.5,10,11 It has been established, though, that the muta-
tions cause a shift in substrate specificity: the mutant
enzyme is able to incorporate, besides serine, alanine and
glycine to form, respectively, 1-deoxysphinganine
(1-deoxy-SA) and 1-deoxymethylsphinganine (1-deoxy-
methyl-SA) instead of sphinganine (SA).12,13 These alterna-
tive metabolites show pronounced neurotoxic effects on
neurite formation in cultured sensory neurons.13
Systematic screening of the knownHSAN genes in a large
series of patients yieldedpathogenicmutations inonly 19%
of probands,6 suggesting the involvement of other disease-
associated genes. Because of the identification of missense
mutations in the SPTLC1 subunit of SPT inHSAN-I patients,
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SPTLC3 as functional candidate genes in a large HSAN
cohort. In this study,we report threeheterozygousmissense
mutations in SPTLC2 in four indexpatients presentingwith
HSAN-I. In in vitro assays as well as in a yeast complemen-
tation assay, we found that the mutations reduce SPT
activity. Additional characterization shows that the three
mutations cause the formation of the neurotoxic metabo-
lite 1-deoxy-SA in human embryonic kidney (HEK) 293
and patient lymphoblast cells. Together with previously
reported findings of HSAN-I-causing SPTLC1 mutations,
our results indicate that mutations in the two SPT subunits
cause a common HSAN pathomechanism.Subjects and Methods
Subjects
For this study, we selected a group of 78 patients with hereditary
ulceromutilating and sensory neuropathies. Our inclusion criteria
were described previously in Rotthier et al.6 Prior to enrollment in
this study, all patients or their legal representatives provided
informed consent of participation to the treating physicians.
This study was approved by the local institutional review board.Mutation Analysis
All DNA samples were amplified with the use of the whole-genome
amplification kit GenomiPhi V2 DNA Amplification Kit (GE
Healthcare). The coding regions and exon-intron boundaries up
to 100 bp up- and downstream of the exons of SPTLC2 and SPTLC3
were amplified via PCR with the use of oligonucleotide primers
designed with the Primer3 and SNPbox software tools.14,15 Primer
sequences are listed in Tables S1 and S2. Mutation screening was
performed by direct DNA sequencing of purified PCR fragments
with the use of the BigDye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems) and separation on an ABI3730xl DNA
Analyzer (Applied Biosystems). The resulting sequences were
alignedandanalyzedwith thenovoSNP16 andSeqMan II programs.
Sequence variants were confirmed by repeated PCR on original
DNA samples and bidirectional sequencing.
Parenthood was tested with the use of 15 highly informative
short tandem repeats (STRs) distributed throughout the genome
(ATA38A05, D1S1646, D1S1653, D1S1360, D2S2256, D3S3037,
D4S2382, D4S3240, D7S509, D8S1759, D9S1118, D12S1056,
D12S2082, D16S2619, and GATA152H04). STRs were amplified
via PCR, and PCR fragments were loaded on an ABI3730xl DNA
Analyzer. Genotypes were analyzed with Local Genotype Viewer.Cloning
The SPTLC2 cDNA (NM_004863.2) was amplified and cloned into
the Gateway entry vector pDONR221 (Invitrogen) with the use
of theprimersSPTLC2_attb1andSPTLC2_attb2. The SPTLC2muta-
tions were introduced by site-directedmutagenesis, with the use of
the following primers: SPTLC2_V359M_fw, SPTLC2_V359M_rv,
SPTLC2_G382V_fw, SPTLC2_G382V_rv, SPTLC2_I504F_fw, and
SPTLC2_I504F_rv. Primer sequences can be found in Table S3.
The constructs were recombined in the destination vector pEF5/
FRT/V5-DEST (Invitrogen), fusing the cDNA with a C-terminal V5
tag. All constructs were validated by sequencing. Stable cell lines
were generated with the use of the Flp-in host cell line HEK293
in accordance with the manufacturer’s instructions (Invitrogen).514 The American Journal of Human Genetics 87, 513–522, OctoberYeast LCB2 together with its own promotor (700 bp upstream of
the start codon) and own terminator (450 bp downstream of the
stop codon) was cloned into the YCplac111 plasmid vector,
harboring a LEU2 gene. Mutations and an HA tag were introduced
by site-directed mutagenesis with the use of the primers
LCB2_HA_fw, LCB2_HA_rv, LCB2_V346M_fw, LCB2_V346M_rv,
LCB2_G369V_fw, LCB2_G369V_rv, LCB2_I491F_fw, LCB2_
I491F_rv, LCB2_K366T_fw, and LCB2_K366T_rv. Primer se-
quences are listed in Table S3.
Cell Culture Material and Conditions
HEK293 Flp-in cells were cultivated at 37C and 5% CO2 in Dul-
becco’s modified Eagle’s medium supplemented with 10% fetal
bovine serum (FBS), L-glutamine, and penicillin and strepto-
mycin. Lymphoblastoid cell lines were cultured at 37C and 5%
CO2 in Roswell Park Memorial Institute medium (RPMI) supple-
mented with 10% FBS, L-glutamine, sodium pyruvate, and peni-
cillin and streptomycin. All cell culture media and supplements
were from Invitrogen.
Lymphoblastoid Cell Lines
Total blood samples were mixed with 15 ml of Ficol Paque and
centrifuged for 10 min. After washing, lymphocytes were trans-
formed with Epstein-Barr virus and incubated at 37C for 2 hr.
After centrifugation, the pellet was resuspended in 4 ml RPMI
complete medium þ 1% phytohaemagglutinin. Cells were seeded
in a 24-well plate and incubated at 37C and 5% CO2 for a
minimum of 3 days. Cells were split and supplemented with fresh
medium as needed.
Yeast Complementation Assay
The YCplac111 constructs containing wild-type (WT) or mutant
LCB2 were transformed17 in a heterozygous LCB2 deletion strain
(BY4743), in which LCB2 has been replaced by a kanamycin-resis-
tance gene, and sporulated. The resulting tetrads were dissected for
the generation of haploid spores that lack endogenous expression
of LCB2, and they were grown on YPD medium with phytosphin-
gosine (15 mM; Avanti Polar Lipids) and 0.1% tergitol at 26C. After
two days, replica plating to different growthmedia was performed,
namely YPD medium at 18C and 37C (yeast SPT mutants have
a thermosensitive growth phenotype18), synthetic minimal
medium without leucine (allowing for selection of transformed
spores), and YPD medium with geneticin (selection of LCB2-defi-
cient spores). For each construct, at least six tetrads were analyzed.
Unless specified otherwise, media and supplements were from
Sigma.
RNA Isolation and mRNA Analysis
Total mRNAwas purified with the RNeasy Mini Kit (Qiagen). DNA
inactivation was performed with the Turbo DNA-free Kit (Am-
bion), and cDNA synthesis was performed with Superscript III
First-Strand Synthesis System for RT-PCR (Invitrogen). Expression
of SPTLC2 (endogenous and construct) was analyzed with the use
of the following primer combinations: SPTLC2_Fw: 50-GAGTCCA
GAGCCAGGTTTTG-30 and SPTLC2_30UTR_Rv: 50-CTGAGGGAG
CACCAAAAAG-30 (for endogenous SPTLC2 expression) or V5_Rv:
50-GAGAGGGTTAGGGATAGGCTTAC-30 (for SPTLC2 construct).
Real-time quantitative PCR (RT-qPCR) reactions were performed
in triplicate with 10 ng cDNA in SYBRGreen Imix (Applied Biosys-
tems) and run on an ABI Prism 7900HT Sequence Detection
System (Applied Biosystems). Primers were validated for specificity8, 2010
and amplification efficiency. RT-qPCR data were normalized
according to the method described by Vandesompele et al.19 The
relative expression levels were used to normalize the data of
the Fumonisin B1 block assay, the in vitro SPT activity assay, and
the 1-deoxy-SA quantification.Fumonisin B1 Block Assay
This assay was performed as described in Penno et al.13 In brief,
Fumonisin B1 (Sigma) was added to the media of exponentially
growing cells in a final concentration of 10 mg/ml. As a negative
control, the SPT inhibitor myriocin (10 mg/ml, Sigma) was
added together with Fumonisin B1. 24 hrs after Fumonisin B1
addition, cells were washed twice with PBS, harvested, and
counted (Coulter Z2, Beckman Coulter). Next, the cells were
subjected to lipid extraction under basic conditions (see below).
Sphingoid bases were quantified by liquid chromatography-mass
spectrometry (LC-MS). Synthetic C17 sphingosine (Avanti Polar
Lipids) was added to each sample as an internal extraction
standard.In Vitro Radioactivity-Based SPT Activity Assay
SPT activity was measured with the use of the radioactivity-based
assay described by Ru¨tti et al.20 In brief, 400 mg total cell lysate,
50 mM HEPES (pH 8.0), 0.5 mM L-serine, 0.05 mM Palmitoyl-
CoA, 20 mM Pyridoxal-50-phosphate, 0.2% sucrose monolaureate
(all from Sigma), and 0.1 mCi L-[U-14C] serine (Amersham) were
mixed and incubated at 37C. In the control reaction, SPT activity
was specifically blocked by the addition of myriocin (40 mM,
Sigma). After 60 min, the reaction was stopped and lipids were ex-
tracted according to the method of Riley et al.21 (see below).Lipid Extraction and Hydrolysis
Total lipids were extracted from cells or plasma according to
the method of Riley et al.21 For acid hydrolysis, the dried lipids
were resuspended in 200 ml methanolic HCl (1N HCl/10M
water in methanol) and kept at 65C for 12–15 hrs. The solution
was neutralized by the addition of 40 ml KOH (5M) and subse-
quently subjected to base hydrolysis, which was performed as
follows: 0.5 ml extraction buffer (4 vol. 0.125M KOH in methanol
þ 1 vol. chloroform) was added to the solution. Subsequently,
0.5 ml chloroform, 0.5 ml alkaline water, and 100 ml 2M ammonia
were added in that order. Liquid phases were separated by centri-
fugation (12,000 g, 5 min). The upper phase was aspirated and
the lower phase washed twice with alkaline water. Finally, the
lipids were dried by evaporation of the chloroform phase under
nitrogen gas and subjected to LC-MS analysis.
Extracted lipids were solubilized in 56.7% methanol-33.3%
ethanol-10% water and derivatized with ortho-phtalaldehyde.
The lipids were separated on a C18 column (Uptispere 120 A˚,
5 mm, 125 3 2 mm, Interchim, France) fluorescence detector
(HP1046A, Hewlet Packard) followed by detection on an MS
detector (LCMS-2010A, Shimadzu). Atmospheric pressure
chemical ionization was used for ionization. Nonnatural C17
sphingosine (Avanti Polar Lipids) was used as internal standard.
Retention times were as follows: C17SO (internal standard):
6 min; sphingosine: 7.5 min; 1-deoxysphingosine: 9 min; 1-deo-
xymethylsphingosine: 10.5 min; SA: 10.5 min; 1-deoxymethyl-
SA: 13 min; 1-deoxy-SA: 13.5 min. MS data were analyzed with
the use of LCMS solution (Shimadzu) and MS Processor v.11
(ACD Labs).The AmericStatistics
The two-tailed unpaired Student’s t test was used for statistical
analysis. Error bars (standard deviation) and p values (Student’s
t test) were calculated on the basis of three independent experi-
ments.Results
Mutations in SPTLC2 Are Associated with HSAN-I
The coding sequence and intron-exon boundaries of
SPTLC2 (chromosome location 14q24.3) were analyzed in
78 patients with HSAN who had been previously screened
and found to be negative formutations in the other known
HSAN genes (SPTLC1, RAB7 [MIM 602298], the complete
coding region of WNK1/HSN2 [MIM 605232], FAM134B
[MIM 613114], NTRK1 [MIM 191315], NGFB [MIM
162030], and CCT5 [MIM 610150]).6,22 We identified three
heterozygous missense mutations in four index patients,
for whom clinical and electrophysiological information is
summarized in Table 1 and Table 2. The mutations were
absent in 300 European control individuals.
A c.1145G>T sequence variation (p.G382V) was found
in two families (CMT-1044 and CMT-1117; Figure 1A).
The proband of family CMT-1117 presented with progres-
sive distal sensory loss and distal muscle weakness in the
lower limbs at the age of 38 yrs. The clinical presentation
was similar in a member of family CMT-1044. In addition,
this patient experienced dysesthesia in hands and feet and
developed osteomyelitis of a thumb. On the basis of haplo-
type analysis, these families were found to be unrelated
(data not shown).
A second heterozygous mutation (c.1075G>A
[p.V359M]) was discovered in an isolated patient (CMT-
747.I:1; Figure 1B). This patient was diagnosed with
HSAN after developing distal sensory dysfunction with a
foot ulceration necessitating amputation of a toe. No signs
of motor or autonomic involvement were noted.
The third mutation (c.1510A>T [p.I504F]) is a heterozy-
gous de novo mutation found in patient CMT-635.II:1,
who presented with an atypical early-onset sensorimotor
neuropathy complicated with ulcerations, osteomyelitis,
and anhidrosis (Figures 1C and 1D). Paternity testing was
performed for confirmation of parenthood.
Nerve conduction studies were performed in all patients,
revealing predominantly axonal sensorimotor neuro-
pathy; this diagnosis was confirmed by a sural nerve biopsy
in patient CMT-747.I:1 (Table 1 and Table 2).
No disease-associated sequence variants were identified
in the coding region or the intron-exon boundaries of
SPTLC3 (chromosome location 20p12.1).SPTLC2 Mutations Are Associated with a Reduction
in SPT Activity
All three mutations in SPTLC2 target highly conserved
amino acids (Figure 2A), rendering it likely that they are
functionally important. We set out to investigate the effectan Journal of Human Genetics 87, 513–522, October 8, 2010 515
Table 1. Clinical Features of Patients with SPTLC2 Mutation
Origin FH AO Pres. Sym. Dis. Dur. Ulc. Ost. Amp.
Sen.
Dys.
Aut.
Dys.
Dist.
Wkn. NCS Additional
Patient: CMT-747.I:1; Mutation: c.1075G>A (p.V359M)
Austria IC 52 yrs ulceration
and
amputation
of great R toe
27 yrs þ (toes) þ þ þ (distal LL) - - axonal/
intermediate
sensorimotor
sural nerve
biopsy:
axonal
neuropathy
in particular
of
unmyelinated
fibers
Patient: CMT-1044.I:2; Mutation c.1145G>T (p.G382V)
Germany D 37 yrs dysesthesia
and sensory
loss,
distal UL
and LL
35 yrs - þ
(thumb R)
- þ severe
distally
panmodal
with
dysesthesia
- þ UL
(0-3/5)
and LL
(0/5)
axonal/
intermediate
sensorimotor
scoliosis, focal
epilepsy; brisk
reflexes UL;
clenched hand
R > L
Patient: CMT-1117.II:1; Mutation: c.1145G>T (p.G382V)
Austria D 38 yrs sensory
loss
in feet
8 yrs - - - þ distally for
touch
and vibration
- þ LL
(2/5)
axonal
sensorimotor
-
Patient: CMT-1117.I:2; Mutation c.1145G>T (p.G382V)
Austria D ? asymptomatic ? - - - þ distally LL
for vibration
- þ LL
(5-/5)
axonal
sensorimotor
type 2 diabetes
(onset: 71 yrs)
Patient: CMT-635.II:1; Mutation c.1510A>T (p.I504F)
Czech
Republic
IC
(de novo)
5 yrs gait
difficulties,
foot
deformities
9 yrs þ (LL) þ - þ þ þ
(LL)
intermediate
sensorimotor
-
FH, familial history; AO, age at onset; Pres. Sym., present symptom(s); Dis. Dur., disease duration; Ulc., ulceration; Ost., osteomyelitis; Amp., amputation; Sen.
Dys., sensory dysfunction; Aut. Dys., autonomic dysfunction; Dist. Wkn., distal weakness; NCS, nerve conduction studies; IC, isolated case; R, right; L, left; LL,
lower limbs; UL, upper limbs; D, dominant; þ, present; -, absent; ?, unknown. For distal weakness, the Medical Research Council scale (0, 1-, 1, 1þ, ., 5-, 5)
is shown in parentheses, indicating the severity of muscle weakness.of these mutations on SPT activity in stably transfected
Flp-in HEK293 cells. The Flp-in system ensures the stable
insertion of a single copy of the transgene at a specific
genomic location. In this way, moderate and equal expres-
sion of the different transgenes is obtained. The cells were
treated for 24 hr with Fumonisin B1, a mycotoxin thatTable 2. Nerve Conduction Studies in Patients with SPTLC2 Mutation
Median M Ulnar M Perone
Patient Age R/L Amp CV Amp CV Amp
Normal values R 4.0 49.0 4.0 49.0 3.0
CMT-747.I:1 79 yrs R 9.7 44.3 - - 0.1
L 8.4 51.0 - - 0.1
CMT-1044.I:2 72 yrs R 0.1 34.0 0.5 37.0 A
CMT-1117.II:1 44 yrs R 6.2 55.0 - - A
CMT-1117.I:2 72 yrs R 9.9 47.0 5.6 51.0 3.0
CMT-635.II:1 14 yrs R 3.8 25.0 2.9 50.0 A
L 2.0 29 2.1 53 A
M, Motor; S, Sensory; Age, age at clinical examination; Amp, amplitude of the ner
A, absent response; -, not measured; R, right; L, left. Italics indicate abnormal val
516 The American Journal of Human Genetics 87, 513–522, Octoberblocks the de novo sphingolipid biosynthesis pathway
downstream of SPT23 (Figure S1). Because condensation
of palmitoyl-CoA and serine by SPT is the rate-limiting
step in the biosynthesis pathway, the resulting accumula-
tion of SA reflects the canonical SPTactivity (incorporation
of L-serine). Stable expression ofWT SPTLC2 resulted in anal M Tibial M Median S Ulnar S Sural S
CV Amp CV Amp CV Amp CV Amp CV
41.0 3.0 41.0 7.0 46.0 2.0 47.0 1.0 44.0
35.7 - - A A - - - -
23.3 - - 0.9 35.2 - - - -
A A A A A A A A A
A A A A A 0.4 38.0 A A
42.0 - - - - - - 2.7 33.0
A A A A A A A A A
A A A - - - - - -
ve action potential (motor: mV; sensory: mV); CV, conduction velocity (in m/s);
ues.
8, 2010
Figure 1. Missense Mutations in SPTLC2
Are Associated with HSAN-I
(A) Sequence trace files of the G382V
mutation in families CMT-1117 (proband
indicated by arrow) and CMT-1044.
(B) Isolated patient CMT-747.I:1 with the
V359M mutation.
(C) Patient CMT-635.II:1 carrying a de
novo I504F mutation.
(D) Severe ulcerations and deformation of
the foot of patient CMT-635.II:1 at the
age of 10 yrs.
Htz, heterozygous; WT, wild type.8-fold increase in SA accumulation as compared to control
cells stably expressing green fluorescent protein (GFP).
This is in agreement with earlier reports, in which overex-
pression of WT SPTLC2 indeed leads to higher SPT
activity.24 Stable expression of the G382V mutant, on the
other hand, did not increase SA accumulation above basal
levels. The V359M- and I504F-expressing cells showed an
increase in SA accumulation, although far less pronounced
than that ofWT SPTLC2-expressing cells (Figure 3A). Thus,
the three mutations result in a partial to complete loss of
SPT activity.
The effect on canonical SPT activity was confirmed in
an alternative radioactive-based in vitro assay. Total lipids
were extracted from HEK293 cells stably expressing WT
or mutant SPTLC2 and incubated with 14C-labeled
L-serine, PLP, and palmitoyl-CoA, after which the incorpo-
ration of the radioactively labeled serine was measured
(Figure 3B). The results resembled those of the previous
assay. Stable expression of WT SPTLC2 caused a significantThe American Journal of Human Geincrease in SPT activity, whereas the
expression of G382V failed to raise
SPT activity above basal levels. Ex-
pression of the V359M or I504F
mutant elevated SPT activity, but not
to the same extent as WT SPTLC2.
The relative increase in SPT activity
in V359M- and I504F-expressing cells
was more pronounced than in the Fu-
monisin B1 block assay (Figure 3A).
This difference could be explained
by the higher serine concentration
used in the latter in vitro assay in
comparison to the serine concentra-
tions present in the cell culture
medium during the former assay.
SPTLC2 Mutants Differentially
Affect In Vivo SPT Activity
in S. cerevisiae
To corroborate the loss of canonical
SPT activity in vivo, we expressed
the corresponding yeast mutants
(Figure 2A) in a heterozygous LCB2
deletion yeast strain (LCB2 is theS. cerevisiae ortholog of SPTLC2) and performed a tetrad
analysis in order to obtain two haploid spores with and
two without endogenous LCB2. As expected, all four
spores grow at the permissive temperatures of 18C,
regardless of whether they express WT or mutant LCB2.
At the restrictive temperature (37C), spores with (residual)
SPT activity will be able to grow, whereas spores with no or
nonfunctional LCB2 will depend on the external addition
of phytosphingosine in order to generate phytosphingoli-
pids and grow.18 WT LCB2 was able to complement the
LCB2 deficiency, as apparent from the appearance of four
equally sized colonies in the absence of phytosphingosine
(Figure 4). In contrast, but analogous to the dominant-
negative LCB2 K366T mutation,25 yeast spores expressing
the G369Vmutation (corresponding to G382V in SPTLC2)
yielded only colonies when endogenous LCB2was present,
demonstrating the failure of this mutant to complement
LCB2 deficiency. The residual activity conferred by the
V346M and I491F mutants (corresponding to V359Mnetics 87, 513–522, October 8, 2010 517
Figure 2. Conservation of Mutations among Species and Structural View of the Bacterial SPT Enzyme
(A) ClustalW multiple protein alignment of the SPTLC2 orthologues from human (Homo sapiens), mouse (Mus musculus), rat (Rattus
norvegicus), taurus (Bos Taurus), zebrafish (Danio rerio), fly (Drosophila melanogaster), baker’s yeast (Saccharomyces cerevisiae), and
Gram-negative bacteria with SPT activity (Sphingomonas paucimobilis).
(B) SPT structure of the Sphingomonas paucimobilis SPT homodimer (PDB ID: 2JGT) with the dimeric subunits represented in red and blue.
The highlighted amino acids (V246, G268, and G385) correspond to the amino acids (V359, G382, and I504) mutated in the HSAN-I
patients (see alignment in A).and I504F, respectively, in SPTLC2) was sufficient to restore
growth at 37C; this is in accordance with our biochemical
data.Mutant SPT Shows Ambiguity towards Its Amino Acid
Substrate
A recent report shows that SPTLC1 mutations in HSAN-I
influence the substrate specificity of the SPT enzyme:
mutant SPT is able to metabolize L-alanine and to a lesser
extent glycine as alternative substrates. This results in the
formation of the atypical and neurotoxic sphingoid base
metabolites 1-deoxy-SA and 1-deoxymethyl-SA.12,13 The
accumulation of these metabolites in the peripheral nerves
was postulated to be the underlying cause of HSAN-I.13 To
study whether SPTLC2 mutations likewise affect the enzy-
matic affinity of SPT and cause a similar accumulation of
these alternative metabolites, we analyzed the sphingoid
base profile of HEK293 cells expressing the mutants.
In cells stably expressing WT SPTLC2, the amount of
1-deoxy-SA was similar to control cells (Figure 5A),
showing that an increase in SPT activity as such does not
alter substrate specificity. Expression of the mutants, on
the other hand, resulted in up to 20-fold higher 1-deoxy-
SA levels in comparison to control cells, the highest levels
in HEK cells stably expressing the G382V or I504F mutant
enzyme. The generation of 1-deoxymethyl-SA levels in
both HEK cells and lymphoblast cells was below detection
limits.
To validate whether the results obtained in the HEK
cells reflect the situation in HSAN-I patients, we measured
1-deoxy-SA levels in lymphoblast cell lines from two
HSAN-I patients carrying, respectively, the G382V and
I504F mutation. In both cell lines, accumulation of
1-deoxy-SA was observed when compared to unaffected518 The American Journal of Human Genetics 87, 513–522, Octoberfamily members or unrelated healthy control individuals
(Figure 5B). This finding is in agreement with our in vitro
results and, more importantly, shows that the accumula-
tion of 1-deoxy-SA could be physiologically relevant.Discussion
We previously reported that only 19% of a cohort of 100
HSAN patients had mutations in the coding regions of
genes known to be mutated in HSAN, suggesting addi-
tional genetic heterogeneity.6 This was strengthened by
our recent identification of FAM134B mutations in
HSAN-II (MIM 613115) patients from this cohort.22
Because mutations in the first subunit of SPT were found
to be associated with HSAN-I,4–6 we screened the two other
subunits of SPT, SPTLC2 and SPTLC3, as functional
candidate genes in 78 patients with hereditary ulceromuti-
lating and sensory neuropathies. This cohort shows a wide
variability of clinical features and different modes of inher-
itance, but all patients share a progressive distal sensory
dysfunction. The functional candidate approach has
been proven to be valuable, especially in the case of rare,
debilitating disorders, in which small pedigrees preclude
the use of classical positional cloning. Althoughmutations
in SPTLC2 were previously excluded as a common cause of
HSAN-I,26 we still supported the strength of this gene as a
functional candidate gene for HSAN. This was based on the
reported effects of the SPTLC1mutations, namely a reduc-
tion in SPT activity and the accumulation of atypical
sphingolipid metabolites; both effects could be envisaged
as resulting from mutations in the other SPT subunits as
well.
No disease-associated mutations were identified in the
third subunit of SPT (SPTLC3) in our HSAN cohort. It was8, 2010
Figure 3. In Vitro SPT Activity Measurements of HSAN-I Associ-
ated SPTLC2 Mutants
(A) Fumonisin B1 block assay. SPT activity in HEK293 cells stably
expressing WT or mutant SPTLC2 is analyzed by measuring SA
accumulation after treatment with Fumonisin B1. Stable expres-
sion of WT SPTLC2 generates an 8.5-fold increase in SPT activity
(p ¼ 3.24 3 105), whereas the G382V mutant does not increase
SPT activity (p ¼ 0.18). The V359M and I504F mutations increase
the activity significantly (p ¼ 0.00063 and 0.00064, respectively)
but not to the same extent as WT SPTLC2. Enhanced GFP
(EGFP)-transfected cells served as control.
(B) Radioactivity-based SPT activity assay. SPT activity of HEK293
cells stably expressing WT or mutant SPTLC2 was determined by
measuring the incorporation of 14C-labeled L-serine in vitro.
Stable expression of WT SPTLC2 results in a significant increase
in SPT activity, whereas the expression of G382V fails to raise
SPT activity above basal levels. Expression of the V359M
or I504F mutant elevates SPT activity, but not as drastically
as WT SPTLC2. The right bars represent SPT activity in the pres-
ence of the SPT inhibitor myriocin (negative control; see
Figure S1).
CPM, counts per minute; SA, sphinganine. *** p < 0.001. Data are
represented as mean, with error bars representing standard devia-
tions. Error bars and standard deviation were calculated on the
basis of three independent experiments.
Figure 4. Genetic Complementation Test in S. cerevisiae by
Tetrad Dissection of a Heterozygous LCB2/lcb2::KanMX Strain
Complemented with Different YCplac111_LCB2 Constructs
WT LCB2 can complement LCB2 deficiency, as shown by the
appearance of four equally sized colonies on YPDmediumwithout
phytosphingosine at 37C. The V346M (corresponding to V359M
in SPTLC2) and I491F (corresponding to I504F in SPTLC2) LCB2
mutants also rescue the absence of endogenous LCB2. However,
yeast transformed with the G369V (corresponding to G382V in
SPTLC2) or K366T (dominant negative) mutants yields only colo-
nies when endogenous LCB2 is present, demonstrating the failure
of these mutants to complement LCB2 deficiency.previously suggested that SPTLC2 and SPTLC3, which are
isoforms, allow for the adjustment of SPT activity to
tissue-specific requirements for sphingolipid synthesis.24
Given the low expression levels of SPTLC3 in neuronal
tissue,24 SPTLC3 is indeed unlikely to have a role in neuro-
logical diseases. Although we cannot completely rule out
mutations in SPTLC3, we exclude mutations in this gene
as a common cause for HSAN.
In SPTLC2, we identified three missense mutations—
V359M, G382V, and I504F—in patients diagnosed with
HSAN-I. The patients carrying the V359M (CMT-747.I:1)The Americand G382V (CMT-1117.II:1 and CMT-1044.I:2) mutations
had a very similar disease course, with adult onset of prom-
inent sensory dysfunction and variable motor involve-
ment. The mother of CMT-1117.II:1, CMT-1117.I:2, who
also carries the G382V mutation, presents with a mild
peripheral neuropathy that was noticed only upon clinical
examination. Because this patient was diagnosed with a
mild form of diabetes, the origin of the peripheral neurop-
athy in this patient is debatable. Of note, many inherited
peripheral neuropathies are associated with a very broad
phenotypic variability, both inter- and intrafamilial,
rendering it well possible that patient CMT-1117.I:2 is
indeed an asymptomatic carrier of this mutation. In our
opinion, this by no means casts doubt on the pathoge-
nicity of the mutation, given that we provided strong
functional evidence for its causative role in HSAN-I
(further discussed below).
The patient with the de novo I504F mutation was
phenotypically distinct, the most remarkable difference
being the onset of the disease in childhood. Moreover,
this patient also experienced autonomic dysfunction,
namely sweating disturbances. It is noteworthy that the
S331F mutation in SPTLC1 is also associated with an
atypical and early-onset HSAN-I phenotype.6 These two
observations clearly illustrate that the phenotypic spec-
trum of this rare disorder is broad and warrants the inclu-
sion of patients with an early disease onset (< 10 yrs) in
future screenings for SPTLC mutations. Furthermore, the
identification of a second gene for HSAN-I and the pres-
ence in our cohort of HSAN-I patients without mutation
in either of the two known genes demonstrate the genetic
heterogeneous nature of this disorder and call for a further
screening of functional candidate genes, such as the
recently identified regulatory interactors of SPT, the smallan Journal of Human Genetics 87, 513–522, October 8, 2010 519
Figure 5. SPTLC2Mutations Affect the Enzymatic Affinity of SPT
(A) Levels of 1-deoxy-SA in HEK293 cells stably expressing WT or
mutant SPTLC2 are measured after an acid and base hydrolysis
assay of the extracted lipids. Expression of WT SPTLC2 does not
change cellular 1-deoxy-SA levels (p ¼ 0.55), whereas all three
HSAN-I-associated mutants result in significantly elevated
1-deoxy-SA levels (p ¼ 0.0025 for V359M; 0.00093 for G382V;
0.00048 for I504F).
(B) 1-deoxy-SA levels in HSAN-I patient lymphoblastoid cell lines.
The two HSAN-I patients CMT-1044.I:2 (G382V mutation) and
CMT-635.II:1 (I504F mutation) show higher levels of 1-deoxy-SA
compared to the unaffected parents of CMT-635.II:1 and to two
unrelated control individuals. Unfortunately, no lymphoblast
cells were available of patient CMT-747.I:1 carrying the V359M
mutation.
*** p value < 0.001. SA, sphinganine. Data are represented as
mean, with error bars representing standard deviations. Error
bars and standard deviation were calculated on the basis of three
independent experiments.stimulatory SPT subunits (ssSPT)27 and the ORMDL
proteins.28,29
The three disease-associated mutations identified in this
study target highly conserved amino acids residing in con-
served domains, possibly indicating functionally impor-
tant domains. In particular, the G382 residue is an active
residue in the putative PLP-binding domain of SPTLC2.30
A study by Gable et al.25 suggests that the known HSAN-I
associated SPTLC1 mutations (C133W, C133Y, V144D)
indirectly affect PLP binding by altering the geometry of
the PLP-binding site in the dimeric conformation. They
tested their hypothesis by mutating amino acids in the
putative PLP-binding domain in LCB2, the yeast ortholog
of SPTLC2. In support of their assumption, the mutations520 The American Journal of Human Genetics 87, 513–522, Octoberdominantly inactivated SPT activity, suggesting that muta-
tions in the PLP-binding domain of SPTLC2 could cause
a phenotype similar to HSAN-I caused by SPTLC1 muta-
tions. On the basis of these observations, together with
the reported decrease of SPT activity for HSAN-I-associated
SPTLC1mutations, the effect of our SPTLC2mutations on
SPT activity was not unexpected. Interestingly, however,
the threemutations have a differential effect on the canon-
ical enzymatic activity. In two independent in vitro assays,
the expression of G382V fails to raise SPT activity above
basal levels, whereas expression of the V359M or I504F
mutant confers limited SPT activity. This duality is also
observed in an in vivo assay: the yeast mutant correspond-
ing to G382V is unable to complement the absence of
endogenous LCB2, whereas the partial activity retained
by the two other mutants suffices to allow growth. It is
possible that the position of the affected amino acids
accounts for the differential effect of the mutations on
SPT activity: the structure of the bacterial (Sphingomonas
paucimobilis) SPT homodimer shows that the G268 residue
(corresponding to G382) resides in the putative interface
between SPTLC1 and SPTLC2, the catalytic domain of
SPT, whereas the other two mutated residues (V246 and
G385, corresponding to V359 and I504) are located on
the surface of the protein (Figure 2). Like WT SPTLC2
protein, mutant SPTLC2 colocalizes with the ER marker
calreticulin in SH-SY5Y neuroblastoma cells (data not
shown), rendering it unlikely that mislocalization of the
mutant protein causes the loss in SPT activity.
Heterozygous Sptlc2 knockout mice, who have only one
copy of SPTLC2, are not known to develop a neuropathy,31
rendering it unlikely that haploinsufficiency is sufficient to
cause the disease. Therefore, we set out to further charac-
terize the effect of the mutations on SPT properties.
Recently, the HSAN-I-associated mutations in SPTLC1
were found to cause the accumulation of the neurotoxic
metabolites 1-deoxy-SA and 1-deoxymethyl-SA. This is
due to a shift in substrate specificity of mutant SPT that
leads to the condensation of palmitoyl-CoA with alanine
and glycine, besides serine.13 Because these 1-deoxy bases
lack the C1 hydroxyl group (Figure S1), they can neither
be degraded nor be converted into complex sphingolipids
by the enzymes of the sphingolipid biosynthesis pathway;
hence, they accumulate in the cell. In our study we found
all three SPTLC2 mutations to be associated with elevated
1-deoxy-SA levels. Highest levels of the 1-deoxy bases
were found in G382V and I504F expressing cells; the levels
in V359M expressing cells were lower, but still significantly
increased in comparison to cells expressing WT SPTLC2.
This finding suggests that altered SPT substrate specificity
could contribute to the disease pathomechanism.
The exogenous addition of 1-deoxy-SA but not of SA has
been shown to be neurotoxic to cultured primary dorsal
root ganglia and, to a lesser extent, motor neurons: it
impairs neurite outgrowth and induces the retraction of
existing neurites, and this is associated with a disturbed
actin-neurofilament interaction.13 However, whether the8, 2010
same neurotoxic mechanisms occur when 1-deoxy-SA is
generated within the neuron is currently unknown. The
mouse model for HSAN-I, overexpressing the SPTLC1
mutation C133W, has highly elevated levels of the atypical
sphingoid bases in the sciatic nerves, whereas brain tissue
is devoid of these metabolites. This is reminiscent of the
pathology in HSAN-I patients, in which the peripheral
nervous system is affected and the central nervous system
spared, and suggests that these atypical bases could be key
in disease development. Interestingly, double transgenic
SPTLC1WT/C133W mice, overexpressing both WT and
mutant SPTLC1, produce levels of 1-deoxy-SA in the sciatic
nerve that are intermediary between levels in WT and
SPTLC1C133W mice, but they do not develop a peripheral
neuropathy.32 This suggests that this metabolite is toler-
ated to a certain extent in the sciatic nerve. Moreover,
the study of Penno et al.13 of seven HSAN-I patients
carrying the SPTLC1 C133W mutation shows a tendency
of levels for 1-deoxy-SA to be higher in patients with a
more severe clinical phenotype. This is in contrast with
our study, in which the levels of 1-deoxy-SA do not seem
to correlate with the severity of the clinical phenotype.
The patient carrying the I504F mutation and showing
high 1-deoxy-SA levels presented with an atypically early
onset of disease, but the patients carrying the G382V
mutation, which is likewise correlated with strongly
increased 1-deoxy-SA levels, had an adulthood disease
onset. Possible explanations for this discrepancy could be
the age of the patient, the disease stage, or the existence
of hitherto unidentified genetic or environmental factors.
Sphingolipids are important structural components of
eukaryotic membranes, but they are also considered to be
key bioactive molecules. Together with cholesterol, they
form the major constituent of the lipid rafts, regions
within the plasma membrane important for cellular sig-
naling. In neurons, they are involved in neurotrophin
signaling, axon guidance, and synaptic transmission.33
Sphingolipids and sphingoid bases are implicated in
various disease processes such as cancer pathology, inflam-
mation, and diabetes,34,35 indicating their role in a myriad
of processes in the cell. With regard to the nervous system,
it is of note that mutations in a high number of enzymes
involved in sphingolipid metabolism are associated with
neurodegenerative diseases.9 With this study, the impor-
tance of the sphingolipid pathway in neurological func-
tioning is once again being stressed.
In conclusion, by using the functional candidate gene
approach we identified mutations in SPTLC2 to be
associated with HSAN. Our finding extends the genetic
variability in HSAN-I and enlarges the group of HSAN
neuropathies associated with SPT defects. We further
show that HSAN-I is consistently associated with an
increased formation of the neurotoxic 1-deoxy-SA, sug-
gesting a common pathomechanism for HSAN-I. The
elucidation of 1-deoxy-SA function and HSAN-I pathology
will further broaden our knowledge of the ever-expanding
field of sphingolipids.The AmericSupplemental Data
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